Danone: Strong and consistent growth in Q3, led by volume/mix
2025 Third-Quarter Sales
Press release – Paris, October 28, 2025, at 7:30 AM CET
Strong and consistent growth in Q3,
led by volume/mix
|
| € million except % | Q3 2024 | Q3 2025 | Reported change | LFL sales growth | Volume/mix growth | 9M 2024 | 9M 2025 | Reported change | LFL sales growth | Volume/mix growth | |
| BY GEOGRAPHICAL ZONE | |||||||||||
| Europe | 2,427 | 2,481 | +2.2% | +2.6% | +2.1% | 7,210 | 7,375 | +2.3% | +2.3% | +2.2% | |
| North America | 1,611 | 1,577 | -2.1% | +1.5% | +0.3% | 4,943 | 4,757 | -3.8% | +2.5% | +1.0% | |
| China, North Asia & Oceania | 967 | 1,032 | +6.7% | +13.8% | +15.1% | 2,808 | 3,048 | +8.6% | +12.1% | +13.0% | |
| Latin America | 706 | 676 | -4.2% | +4.3% | -2.3% | 2,265 | 2,066 | -8.8% | +5.2% | -2.5% | |
| Asia, Middle East & Africa | 1,115 | 1,111 | -0.4% | +6.8% | +2.6% | 3,350 | 3,332 | -0.5% | +4.8% | +1.0% | |
| BY CATEGORY | |||||||||||
| EDP | 3,283 | 3,255 | -0.9% | +3.5% | +1.7% | 10,066 | 9,853 | -2.1% | +3.4% | +1.8% | |
| Specialized Nutrition | 2,189 | 2,299 | +5.0% | +8.3% | +6.5% | 6,599 | 6,904 | +4.6% | +7.5% | +5.5% | |
| Waters | 1,354 | 1,322 | -2.3% | +2.3% | +1.3% | 3,910 | 3,822 | -2.2% | +1.8% | +0.6% | |
| TOTAL | 6,826 | 6,876 | +0.7% | +4.8% | +3.2% | 20,575 | 20,578 | +0.0% | +4.4% | +2.8% |
1
Antoine de Saint-Affrique: CEO statement
We continued to deliver consistent, quality growth this quarter, with volume/mix being the primary growth driver across our categories, confirming the strength and the relevance of our health-focused portfolio.
We are particularly pleased with the step-by-step improvement in Europe, where volume/mix has now been positive for eight consecutive quarters, while CNAO delivered another outstanding performance across all categories. At the same time, we recognize that our transformation journey is not over and that some areas require further progress. We stay focused on fully leveraging our science-based and value-added portfolio, while continuing to execute with discipline and agility.
In what remains a volatile and uncertain environment, we are confident in our direction, deploying chapter two of our Renew Danone strategy to deliver on our mid-term ambition.
I. THIRD QUARTER SALES
In Q3 2025, consolidated sales stood at €6,876m, up +4.8% on a like-for-like basis, led by an increase of +3.2% from volume/mix and +1.6% from price. On a reported basis, sales increased by +0.7%, including a positive impact from scope (+0.7%) resulting predominantly from the acquisition of Kate Farms in the US (completed on July 1st, 2025). Reported sales were negatively impacted by forex (-5.1%), reflecting the depreciation of several currencies against the euro, notably the US Dollar, the Chinese Renminbi, the Indonesian Rupiah, the Argentine Peso and the Turkish Lira. In addition, hyperinflation contributed positively to reported sales (+0.3%).
Sales by operating segment
In Q3 2025, Europecontinued to step-up with sales growth of +2.6% LFL, led by volume/mix up +2.1%, and positive price, up +0.5%. Sustained progress in EDP was driven by functional dairy, notably Danone Skyr, Activia Kefirand YoProhigh protein, as well as Alpro.Specialized Nutrition posted a solid quarter, with double-digit growth in adult medical nutrition, while eviandrove robust growth in Waters.
In North America, sales were up +1.5% LFL, with +0.3% volume/mix and +1.2% price. Momentum remained strong in high protein, with new innovations launched during the quarter. Coffee Creamers are progressively regaining competitiveness. Plant-based remains work in progress. Medical Nutrition delivered a good performance, and recently acquired Kate Farms showed positive dynamics, not yet included in the LFL figure.Finally, evian drove strong growth in Waters.
China, North Asia & Oceania delivered an outstanding performance, with strong momentum in all categories. Sales were up +13.8% LFL, driven by volume/mix of +15.1%, and price of -1.3%. Specialized Nutrition saw consistently strong growth in both Infant Milk Formula and Medical Nutrition. Souvenaid contributed to strong growth in Oceania. In Waters, Mizonesustained its solid dynamics, while in EDP, Activia and Oikos delivered double-digit growth in Japan.
Latin America posted a solid performance amid challenging markets, with sales up +4.3% LFL, including -2.3% volume/mix and +6.6% price. Specialized Nutrition delivered double-digit growth across the region, driven by Aptamil. EDP recorded a strong performance, supported by Danone, Oikos Greek and YoPro. Waters continued to be impacted by a subdued beverage market in Mexico.
In Asia, Middle East and Africa, sales growth accelerated to +6.8% LFL, with a solid contribution from volume/mix, up +2.6%, and price up +4.2%. Specialized Nutrition posted another quarter of strong growth, driven by Aptamil. Strong momentum continued in Dairy Africa, led by Danone and Activia, while the performance in Waters improved, including in volume/mix.
Sales by geography by category
| Q3 2025 | Europe | North America | China, North Asia & Oceania | AMEA & Latin America | Total | |||||
| Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | |
| EDP | 1,087 | +2.1% | 1,365 | +1.5% | 103 | +14.5% | 701 | +8.7% | 3,255 | +3.5% |
| Specialized Nutrition | 789 | +3.0% | 136 | +0.1% | 678 | +17.0% | 696 | +7.6% | 2,299 | +8.3% |
| Waters | 605 | +3.0% | 77 | +5.0% | 251 | +5.6% | 390 | -1.3% | 1,322 | +2.3% |
| Total Company | 2,481 | +2.6% | 1,577 | +1.5% | 1,032 | +13.8% | 1,787 | +5.9% | 6,876 | +4.8% |
| 9M 2025 | Europe | North America | China, North Asia & Oceania | AMEA & Latin America | Total | |||||
| Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | Sales (€m) | LFL sales growth (%) | |
| EDP | 3,292 | +1.7% | 4,199 | +2.2% | 305 | +10.5% | 2,058 | +7.8% | 9,853 | +3.4% |
| Specialized Nutrition | 2,399 | +2.6% | 325 | +5.3% | 2,048 | +14.2% | 2,132 | +7.1% | 6,904 | +7.5% |
| Waters | 1,684 | +2.9% | 233 | +3.9% | 696 | +6.9% | 1,209 | -2.6% | 3,822 | +1.8% |
| Total Company | 7,375 | +2.3% | 4,757 | +2.5% | 3,048 | +12.1% | 5,399 | +4.9% | 20,578 | +4.4% |
II. 2025 GUIDANCE
2025 guidance confirmed, in line with mid-term ambition: LFL sales growth expected between +3% and +5%, with recurring operating income growing faster than sales.
III. RECENT MAJOR DEVELOPMENTS
- June 25, 2025: Danone announced the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics. Expanding deeper into gut health is a key facet of Danone’s Renew strategy, as it doubles down on science and innovation, and as consumer interest in healthy products continues to rise.
- July 1st, 2025: Danone successfully completed the acquisition of a majority stake in Kate Farms, a fast-growing U.S. business and the #1 doctor-recommended plant-based brand in the U.S.2, offering a wide array of organic, plant-based nutrition products for both medical and everyday needs.
- August 26, 2025: Danone announced an evolution of its leadership structure. The company will operate through 3 geographies: EMEA, Asia Pacific and Americas. This leaner organization marks a further step in the deployment of the second chapter of Renew Danone. It will further enhance the company’s agility and market impact. To this effect, as of January 1st, 2026,
- Pablo Perversi is appointed President EMEA (Europe, Turkey, Middle East and Africa),
- Bruno Chevot is appointed President APAC (Asia-Pacific),
- and Henri Bruxelles is appointed President Americas.
all reporting to Véronique Penchienati-Bosetta, Group Deputy CEO, in charge of geographies and categories.
- September 1st, 2025: Danone announced it has launched a €1.3 billion dual-tranche bond issue, consisting of:
- a tranche of 2-year floating rate notes of €800 million (coupon of Euribor 3 months +27 basis points);
- a tranche of undated deeply subordinated fixed rate resettable notes of €500 million (fixed resettable coupon of 3.95% with a first call date on 8 September 2032).
Proceeds of this issue will be used for the general corporate purposes, including, for the undated deeply subordinated notes, to refinance Danone 's existing €500 million undated deeply subordinated fixed rate resettable notes callable in September 2026 (ISIN: FR0014005EJ6). The undated deeply subordinated notes will be fully accounted as equity in accordance with IFRS standards and will be treated as 50% equity by Moody’s and Standard & Poor’s in their credit metrics. The settlement took place on September 8, 2025, and the bonds are listed on Euronext Paris.
- September 29, 2025: Danone inaugurated its OneBiome Laboratory in Paris-Saclay, marking a major milestone in its commitment to science-based innovation and leadership in gut health research. The Danone OneBiome Lab will serve as a global hub for microbiome science, nutrition, and digital health, reinforcing Danone’s pioneering role in shaping the future of food and health.
IV. ALTERNATIVE PERFORMANCE MEASURES NOT DEFINED BY IFRS
IAS 29: impact on reported data
Danone has applied IAS 29 in hyperinflationary countries, as defined in IFRS. Adoption of IAS 29 in hyperinflationary countries requires their non-monetary assets and liabilities and their income statement to be restated to reflect the changes in the general purchasing power of their functional currencies, leading to a gain or loss on the net monetary position, included in the net income. Moreover, their financial statements are converted into euros using the closing exchange rate of the relevant period.
| IAS 29: impact on reported data | Q3 2025 |
| Sales (€ million) | +13.8 |
| Sales growth (%) | +0.20% |
Breakdown by quarter of 9M 2025 sales after application of IAS 29
9M 2025 sales correspond to the addition of:
- Q3 2025 reported sales;
- Q1 and Q2 2025 sales resulting from the application of IAS 29 until September 30, 2025, to sales of entities in hyperinflation countries (application of the inflation rate until September 30, 2025, and translation into euros using the September 30, 2025, closing rate) and provided in the table below for information (unaudited data)
| Sales after application of IAS 29 (€ million) | Q1 20251 | Q2 20252 | Q3 2025 | 9M 2025 |
| BY GEOGRAPHICAL ZONE | ||||
| Europe | 2,389 | 2,505 | 2,481 | 7,375 |
| North America | 1,633 | 1,546 | 1,577 | 4,757 |
| China, North Asia & Oceania | 936 | 1,080 | 1,032 | 3,048 |
| Latin America | 686 | 704 | 676 | 2,066 |
| Asia, Middle East & Africa | 1,167 | 1,055 | 1,111 | 3,332 |
BY CATEGORY | ||||
| EDP | 3,359 | 3,239 | 3,255 | 9,853 |
| Specialized Nutrition | 2,298 | 2,307 | 2,299 | 6,904 |
| Waters | 1,155 | 1,345 | 1,322 | 3,822 |
| Total | 6,811 | 6,891 | 6,876 | 20,578 |
1Results from the application of IAS 29 until September 30,2025, to Q1 sales of entities of hyperinflation countries.
2Results from the application of IAS 29 until September 30, 2025, to Q2 sales of entities of hyperinflation countries.
Definitions of geographical zones
Europerefers to European countries.
North Americarefers to the United States and Canada.
China, North Asia & Oceaniarefers to China, Japan, Australia and New-Zealand.
Latin Americarefers to Mexico, Brazil, Argentina and Uruguay.
Asia, Middle East & Africarefers to refers to Asia, Middle East including Turkey, Africa and CIS (zone previously called “Rest of the World”).
Financial indicators not defined in IFRS
Due to rounding, the sum of values presented may differ from totals as reported. Such differences are not material.
Like-for-like changesin sales reflect Danone 's organic performance and essentially exclude the impact of:
- changes in consolidation scope, with indicators related to a given fiscal year calculated on the basis of the previous year 's scope;
- changes in applicable accounting principles;
- changes in exchange rates, with both previous-year and current-year indicators calculated using the same exchange rate (the exchange rate used is a projected annual rate determined by Danone for the current year and applied to both previous and current years).
Since January 1st, 2023, all countries with hyperinflationary economies are taken into account in like-for-like changes as follows: sales growth in excess of around 26% per year (a three-year average at 26% would generally trigger the application of hyperinflationary accounting as defined in IFRS) is now excluded from the like-for-like sales growth calculation.
Bridge from like-for-like data to reported data
| (€ million except %) | 2024 sales | Like-for-like change | Impact of changes in scope of consolidation | Impact of changes in exchange rates & others incl. IAS 29 | Contribution of hyperinflation | Reported change | 2025 sales |
| Q3 | 6,826 | +4.8% | +0.7% | -5.1% | +0.3% | +0.7% | 6,876 |
| 9M | 20,575 | +4.4% | -0.8% | -4.3% | +0.6% | +0.0% | 20,578 |
Recurring operating income is defined as Danone’s operating income excluding Other operating income and expenses. Other operating income and expenses comprise items that, because of their significant or unusual nature, cannot be viewed as inherent to Danone’s recurring activity and have limited predictive value, thus distorting the assessment of its recurring operating performance and its evolution. These mainly include:
- capital gains and losses on disposals of businesses and fully consolidated companies;
- under IAS 36, impairment charges on intangible assets with indefinite useful lives;
- costs related to strategic restructuring operations or transformation plans;
- costs related to major external growth transactions;
- costs related to crises and major disputes;
- in connection with IFRS 3 and IFRS 10, (i) acquisition costs related to acquisitions of companies resulting in control, (ii) revaluation gains or losses accounted for following a loss of control, and (iii) changes in earn-outs subsequent to acquisitions resulting in control.
Recurring operating marginis defined as the Recurring operating income over Sales ratio.
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements concerning Danone that are subject to risks and uncertainties. In some cases, you can identify these forward-looking statements by forward-looking words, such as “estimate”, “expect”, “anticipate”, “project”, “plan”, “intend”, “objective”, “believe”, “forecast”, “guidance”, “foresee”, “likely”, “may”, “should”, “goal”, “target”, “might”, “will”, “could”, “predict”, “continue”, “convinced” and “confident,” the negative or plural of these words and other comparable terminology, or by using future dates. Forward looking statements in this document include, but are not limited to, predictions of future activities, operations, direction, performance and results of Danone.
These forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties, please refer to the “Risk Factors” section of Danone’s Universal Registration Document (the current version of which is available atwww.danone.com).
Subject to regulatory requirements, Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell, or a solicitation of an offer to buy Danone securities.
The presentation to analysts and investors will be broadcast live today from 8:00 a.m. (Paris time)
on Danone’s website (www.danone.com).
Related slides will also be available on the website in the Investors section.
APPENDIX – Sales by geographical zone and by category (in € million)
| Q1 | Q2 | Q3 | |||||||||
| 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | ||||||
BY GEOGRAPHICAL ZONE | |||||||||||
| Europe | 2,336 | 2,389 | 2,447 | 2,505 | 2,427 | 2,481 | |||||
| North America | 1,737 | 1,633 | 1,595 | 1,546 | 1,611 | 1,577 | |||||
| China, North Asia & Oceania | 840 | 936 | 1,001 | 1,080 | 967 | 1,032 | |||||
| Latin America | 727 | 715 | 810 | 714 | 706 | 676 | |||||
| Asia, Middle East & Africa | 1,150 | 1,170 | 1,084 | 1,067 | 1,115 | 1,111 | |||||
BY CATEGORY | |||||||||||
| EDP | 3,474 | 3,381 | 3,298 | 3,261 | 3,283 | 3,255 | |||||
| Specialized Nutrition | 2,183 | 2,306 | 2,213 | 2,307 | 2,189 | 2,299 | |||||
| Waters | 1,132 | 1,156 | 1,426 | 1,345 | 1,354 | 1,322 | |||||
| TOTAL | 6,789 | 6,844 | 6,938 | 6,913 | 6,826 | 6,876 |
| Q1 2025 | Q2 2025 | Q3 2025 | |||||||
| Reported change | LFL change | Reported change | LFL change | Reported change | LFL change | ||||
BY GEOGRAPHICAL ZONE | |||||||||
| Europe | +2.3% | +2.0% | +2.4% | +2.2% | +2.2% | +2.6% | |||
| North America | -5.9% | +3.7% | -3.0% | +2.3% | -2.1% | +1.5% | |||
| China, North Asia & Oceania | +11.5% | +9.9% | +7.9% | +12.4% | +6.7% | +13.8% | |||
| Latin America | -1.6% | +9.0% | -11.9% | +2.9% | -4.2% | +4.3% | |||
| Asia, Middle East & Africa | +1.7% | +3.3% | -1.6% | +4.1% | -0.4% | +6.8% | |||
BY CATEGORY | |||||||||
| EDP | -2.7% | +3.7% | -1.1% | +3.0% | -0.9% | +3.5% | |||
| Specialized Nutrition | +5.7% | +5.3% | +4.2% | +8.7% | +5.0% | +8.3% | |||
| Waters | +2.2% | +4.1% | -5.7% | -0.5% | -2.3% | +2.3% | |||
| TOTAL | +0.8% | +4.3% | -0.4% | +4.1% | +0.7% | +4.8% |
All references in this document to Like-for-like (LFL) changes, and Recurring operating income and margin, correspond to alternative performance measures not defined by IFRS. Their definitions and their reconciliation with financial statements, as well as the definitions of geographical zones, are listed on pages 3 to 5.
2among surveyed doctors recommending plant-based nutrition products.
Attachment
© 2025 GlobeNewswire, Inc. All Rights Reserved.
